Rallybio Corporation
RLYB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9,491.4% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9,084.1% | – | – | – |
| EPS Diluted | -1.33 | -1.84 | -2.09 | -1.46 |
| % Growth | 27.7% | 12% | -43.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |